Epredia
Private Company
Funding information not available
Overview
Epredia, a subsidiary of PHC Holdings Corporation, is a commercial-stage company focused on the diagnostics and medical devices sectors, specifically in anatomic pathology. It offers a comprehensive portfolio including tissue processors, slide printers, and the FDA-cleared E1000 Dx Digital Pathology Solution. Founded in 2019, the company operates globally from its U.S. headquarters, serving as a critical infrastructure provider for cancer diagnostic workflows.
Technology Platform
Integrated anatomic pathology workflow platform encompassing histology instruments (tissue processors, slide printers), consumables, and FDA-cleared digital pathology solutions (scanners and image management software).
Funding History
1Opportunities
Risk Factors
Competitive Landscape
Epredia competes in a crowded market dominated by large corporations like Roche (Ventana), Danaher (Leica Biosystems), and Philips in digital pathology, and Thermo Fisher Scientific and Sakura Finetek in histology. Its strategy is to differentiate through a broad, integrated product portfolio and a legacy of trust in traditional histology to cross-sell digital solutions.